01:25 PM EST - Nova Mentis Life Science Corp : Announces that it has consummated a contract with the Toronto Institute of Pharmaceutical Technology to formulate and manufacture psilocybin microdose capsules for its upcoming Canadian Phase 2A fragile X syndrome clinical study. Nova Mentis Life Science Corp
shares C.NOVA are trading up 6.67% at $0.08.
